Skip to content
2000
Volume 26, Issue 8
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

Rare diseases present unique challenges in drug discovery and development, primarily due to small patient populations, limited clinical data, and significant variability in disease mechanisms. The primary objective of this review is to examine the integration of pharmacokinetics (PK) and drug metabolism data into data-driven drug discovery approaches, particularly in the context of rare diseases. By incorporating advanced computational techniques such as Machine Learning (ML) and Artificial Intelligence (AI), researchers can better predict PK parameters, optimize drug candidates, and identify personalized therapeutic strategies. AI integration with genomic and proteomic data reveals previously unidentifiable pathways, fostering collaboration among researchers, clinicians, and pharmaceutical companies. This interdisciplinary approach reduces development timelines and costs while enhancing the precision and effectiveness of therapies for patients with rare diseases. This review highlights the critical role of absorption, distribution, metabolism, and excretion (ADME) in understanding drug behavior in genetically diverse populations, thereby enabling the development of tailored treatments for patients with rare diseases. Additionally, it evaluates the opportunities and limitations of integrating PK/PD (pharmacodynamics) models with multi-omics data to improve drug discovery efficiency. Key examples of enzyme-drug interactions, metabolic pathway analysis, and AI-based PK simulations are discussed to illustrate advancements in predictive accuracy and drug safety. This review concludes by emphasizing the transformative potential of integrating PK and metabolism studies into the broader framework of data-driven drug discovery, ultimately accelerating therapeutic innovation and addressing unmet medical needs in rare diseases.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002383220250729100138
2025-08-25
2026-02-24

  • From This Site

    /content/journals/cdm/10.2174/0113892002383220250729100138
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HuF. YangH. QiuL. WeiS. HuH. ZhouH. Spatial structure and organization of the medical device industry urban network in China: Evidence from specialized, refined, distinctive, and innovative firms.Front. Public Health202513151832710.3389/fpubh.2025.1518327 40161027
     [Google Scholar]
  2. QiuL. YuR. HuF. ZhouH. HuH. How can China’s medical manufacturing listed firms improve their technological innovation efficiency? An analysis based on a three-stage DEA model and corporate governance configurations.Technol. Forecast. Soc. Change202319412268410.1016/j.techfore.2023.122684
     [Google Scholar]
  3. XingY. YangK. LuA. MackieK. GuoF. Sensors and devices guided by artificial intelligence for personalized pain medicine.Cyborg Bionic Syst.20245016010.34133/cbsystems.016039282019
     [Google Scholar]
  4. AbdallahS. SharifaM. I Kh AlmadhounM.K. KhawarM.M. ShaikhU. BalabelK.M. SalehI. ManzoorA. MandalA.K. EkomwererenO. KhineW.M. OyelajaO.T. The impact of artificial intelligence on optimizing diagnosis and treatment plans for rare genetic disorders.Cureus20231510e4686010.7759/cureus.46860 37954711
     [Google Scholar]
  5. DecherchiS. PedriniE. MordentiM. CavalliA. SangiorgiL. Opportunities and challenges for machine learning in rare diseases.Front. Med.2021874761210.3389/fmed.2021.747612 34676229
     [Google Scholar]
  6. HasaniN. FarhadiF. MorrisM.A. NikpanahM. RahmimA. XuY. PariserA. CollinsM.T. SummersR.M. JonesE. SiegelE. SabouryB. Artificial intelligence in medical imaging and its impact on the rare disease community: Threats, challenges and opportunities.PET Clin.2022171132910.1016/j.cpet.2021.09.009 34809862
     [Google Scholar]
  7. HirschM.C. RonickeS. KruscheM. WagnerA.D. Rare diseases 2030: How augmented AI will support diagnosis and treatment of rare diseases in the future.Ann. Rheum. Dis.202079674074310.1136/annrheumdis‑2020‑217125 32209541
     [Google Scholar]
  8. FaviezC. ChenX. GarcelonN. NeurazA. KnebelmannB. SalomonR. LyonnetS. SaunierS. BurgunA. Diagnosis support systems for rare diseases: A scoping review.Orphanet J. Rare Dis.20201519410.1186/s13023‑020‑01374‑z 32299466
     [Google Scholar]
  9. LeeJ. LiuC. KimJ. ChenZ. SunY. RogersJ.R. ChungW.K. WengC. Deep learning for rare disease: A scoping review.J. Biomed. Inform.202213510422710.1016/j.jbi.2022.104227 36257483
     [Google Scholar]
  10. SiddiqM. Revolutionizing drug discovery; Transformative role of machine learning.BULLET: Jurnal Multidisiplin Ilmu2022102162170
     [Google Scholar]
  11. PaulD. SanapG. ShenoyS. KalyaneD. KaliaK. TekadeR.K. Artificial intelligence in drug discovery and development.Drug Discov. Today2021261809310.1016/j.drudis.2020.10.010 33099022
     [Google Scholar]
  12. BonioloF. DorigattiE. OhnmachtA.J. SaurD. SchubertB. MendenM.P. Artificial intelligence in early drug discovery enabling precision medicine.Expert Opin. Drug Discov.2021169991100710.1080/17460441.2021.1918096 34075855
     [Google Scholar]
  13. DavenportT. KalakotaR. The potential for artificial intelligence in healthcare.Future Healthc. J.201962949810.7861/futurehosp.6‑2‑94 31363513
     [Google Scholar]
  14. JumperJ. EvansR. PritzelA. GreenT. FigurnovM. RonnebergerO. TunyasuvunakoolK. BatesR. ŽídekA. PotapenkoA. BridglandA. MeyerC. KohlS.A.A. BallardA.J. CowieA. Romera-ParedesB. NikolovS. JainR. AdlerJ. BackT. PetersenS. ReimanD. ClancyE. ZielinskiM. SteineggerM. PacholskaM. BerghammerT. BodensteinS. SilverD. VinyalsO. SeniorA.W. KavukcuogluK. KohliP. HassabisD. Highly accurate protein structure prediction with AlphaFold.Nature2021596787358358910.1038/s41586‑021‑03819‑2 34265844
     [Google Scholar]
  15. LiuG. CatacutanD.B. RathodK. SwansonK. JinW. MohammedJ.C. Chiappino-PepeA. SyedS.A. FragisM. RachwalskiK. MagolanJ. SuretteM.G. CoombesB.K. JaakkolaT. BarzilayR. CollinsJ.J. StokesJ.M. Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii.Nat. Chem. Biol.202319111342135010.1038/s41589‑023‑01349‑8 37231267
     [Google Scholar]
  16. WongF. ZhengE.J. ValeriJ.A. DonghiaN.M. AnahtarM.N. OmoriS. LiA. Cubillos-RuizA. KrishnanA. JinW. MansonA.L. FriedrichsJ. HelbigR. HajianB. FiejtekD.K. WagnerF.F. SoutterH.H. EarlA.M. StokesJ.M. RennerL.D. CollinsJ.J. Discovery of a structural class of antibiotics with explainable deep learning.Nature2024626799717718510.1038/s41586‑023‑06887‑8 38123686
     [Google Scholar]
  17. HasselgrenC. OpreaT.I. Artificial intelligence for drug discovery: Are we there yet?Annu. Rev. Pharmacol. Toxicol.20246452755010.1146/annurev‑pharmtox‑040323‑040828 37738505
     [Google Scholar]
  18. AlizadehsaniR. OyelereS.S. HussainS. CalixtoR.R. de AlbuquerqueV.H.C. Explainable artificial intelligence for drug discovery and development—A comprehensive survey.arXiv2023arXiv:2309.12177v210.48550/arXiv.2309.12177
     [Google Scholar]
  19. DoronG. GenwayS. RobertsM. JastiS. New Horizons: Pioneering Pharmaceutical R&D with Generative AI from lab to the clinic—An industry perspective.arXiv2023arXiv:2312.12482v110.48550/arXiv.2312.12482
     [Google Scholar]
  20. GuptaA. CardiGraphormer: Unveiling the power of self-supervised learning in revolutionizing drug discovery.arXiv2023arXiv:2307.00859v410.48550/arXiv.2307.00859
     [Google Scholar]
  21. TambuyzerE. VandendriesscheB. AustinC.P. BrooksP.J. LarssonK. Miller NeedlemanK.I. ValentineJ. DaviesK. GroftS.C. PretiR. OpreaT.I. PrunottoM. Therapies for rare diseases: Therapeutic modalities, progress and challenges ahead.Nat. Rev. Drug Discov.20201929311110.1038/s41573‑019‑0049‑9 31836861
     [Google Scholar]
  22. LiuJ. BarrettJ.S. LeonardiE.T. LeeL. RoychoudhuryS. ChenY. TrifillisP. Natural history and real-world data in rare diseases: Applications, limitations, and future perspectives.J. Clin. Pharmacol.202262S2S38S55(Suppl. 2)10.1002/jcph.213436461748
     [Google Scholar]
  23. PengJ. JuryE.C. DönnesP. CiurtinC. Machine learning techniques for personalised medicine approaches in immune-mediated chronic inflammatory diseases: Applications and challenges.Front. Pharmacol.20211272069410.3389/fphar.2021.720694 34658859
     [Google Scholar]
  24. QuaziS. RETRACTED ARTICLE: Artificial intelligence and machine learning in precision and genomic medicine.Med. Oncol.202239812010.1007/s12032‑022‑01711‑1 35704152
     [Google Scholar]
  25. SchaeferJ. LehneM. SchepersJ. PrasserF. ThunS. The use of machine learning in rare diseases: A scoping review.Orphanet J. Rare Dis.202015114510.1186/s13023‑020‑01424‑6
     [Google Scholar]
  26. Kumar TripathiM. NathA. SinghP. Evolving scenario of big data and artificial intelligence (AI) in drug discovery.Mol. Divers.20212531439146010.1007/s11030‑021‑10256‑w 34159484
     [Google Scholar]
  27. WojtaraM. RanaE. RahmanT. KhannaP. SinghH. Artificial intelligence in rare disease diagnosis and treatment.Clin. Transl. Sci.202316112106211110.1111/cts.13619
     [Google Scholar]
  28. StankevičiūtėK. WoillardJ-B. PeckR.W. MarquetP. van der SchaarM. Bridging the worlds of pharmacometrics and machine learning.Clin. Pharmacokinet.202362111551156510.1007/s40262‑023‑01310‑x 37803104
     [Google Scholar]
  29. BrasilS. NevesC.J. RijoffT. FalcãoM. ValadãoG. VideiraP.A. dos Reis FerreiraV. Artificial intelligence in epigenetic studies: Shedding light on rare diseases.Front. Mol. Biosci.2021864801210.3389/fmolb.2021.648012 34026829
     [Google Scholar]
  30. TiwariP.C. PalR. ChaudharyM.J. NathR. Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges.Drug Dev. Res.20238481652166310.1002/ddr.22115 37712494
     [Google Scholar]
  31. HallowellN. BadgerS. McKayF. KerasidouA. NellåkerC. Democratising or disrupting diagnosis? Ethical issues raised by the use of AI tools for rare disease diagnosis.SSM Qual. Res. Health2023310024010.1016/j.ssmqr.2023.100240 37426704
     [Google Scholar]
  32. DentonN. MulbergA.E. MolloyM. CharlestonS. FajgenbaumD.C. MarshE.D. HowardP. Sharing is caring: A call for a new era of rare disease research and development.Orphanet J. Rare Dis.202217138910.1186/s13023‑022‑02529‑w 36303170
     [Google Scholar]
  33. SahuM. GuptaR. AmbastaR.K. KumarP. Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis.Prog. Mol. Biol. Transl. Sci.202219015710010.1016/bs.pmbts.2022.03.002 36008002
     [Google Scholar]
  34. GangwalA. AnsariA. AhmadI. AzadA.K. Wan SulaimanW.M.A. Current strategies to address data scarcity in artificial intelligence-based drug discovery: A comprehensive review.Comput. Biol. Med.202417910873410.1016/j.compbiomed.2024.108734 38964243
     [Google Scholar]
  35. SiramshettyV.B. XuX. ShahP. Artificial intelligence in ADME property prediction.Methods Mol. Biol.2024271430732710.1007/978‑1‑0716‑3441‑7_17 37676606
     [Google Scholar]
  36. DuB-X. LongY. LiX. WuM. ShiJ-Y. CMMS-GCL: Crossmodality metabolic stability prediction with graph contrastive learning.Bioinformatics2023398btad503Aug;10.1093/bioinformatics/btad503
     [Google Scholar]
  37. PillaiN. AbosA. TeutonicoD. MavroudisP.D. Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure.Clin. Transl. Sci.2024175e1382410.1111/cts.13824 38752574
     [Google Scholar]
  38. SubramanianM. WojtusciszynA. FavreL. BoughorbelS. ShanJ. LetaiefK.B. PitteloudN. ChouchaneL. Precision medicine in the era of artificial intelligence: Implications in chronic disease management.J. Transl. Med.202018147210.1186/s12967‑020‑02658‑5 33298113
     [Google Scholar]
  39. NadellaG.S. SatishS. MeduriK. MeduriS.S. A systematic literature review of advancements, challenges and future directions of AI and ML in healthcare.Int. J. Mach Learn. Sustain. Dev.202353115130
     [Google Scholar]
  40. RoesslerH.I. KnoersN.V.A.M. van HaelstM.M. van HaaftenG. Drug repurposing for rare diseases.Trends Pharmacol. Sci.202142425526710.1016/j.tips.2021.01.003 33563480
     [Google Scholar]
  41. VatanseverS. SchlessingerA. WackerD. KaniskanH.Ü. JinJ. ZhouM.M. ZhangB. Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions.Med. Res. Rev.20214131427147310.1002/med.21764 33295676
     [Google Scholar]
  42. LiY. WangZ. LiY. DuJ. GaoX. LiY. LaiL. A combination of machine learning and pbpk modeling approach for pharmacokinetics prediction of small molecules in humans.Pharm. Res.20244171369137910.1007/s11095‑024‑03725‑y
     [Google Scholar]
  43. FengX. MaZ. YuC. XinR. MRNDR: Multihead attention-based recommendation network for drug repurposing.J. Chem. Inf. Model.20246472654266910.1021/acs.jcim.3c01726 38373300
     [Google Scholar]
  44. ZhouY. LiQ. PanR. WangQ. ZhuX. YuanC. CaiF. GaoY. CuiY. Regulatory roles of three miRNAs on allergen mRNA expression in Tyrophagus putrescentiae.Allergy202277246948210.1111/all.15111 34570913
     [Google Scholar]
  45. ZhouY. LiL. YuZ. GuX. PanR. LiQ. YuanC. CaiF. ZhuY. CuiY. Dermatophagoides pteronyssinusallergen Der p 22: Cloning, expression, IgE ‐binding in asthmatic children, and immunogenicity.Pediatr. Allergy Immunol.2022338e1383510.1111/pai.13835 36003049
     [Google Scholar]
  46. LiJ.P.O. LiuH. TingD.S.J. JeonS. ChanR.V.P. KimJ.E. SimD.A. ThomasP.B.M. LinH. ChenY. SakomotoT. LoewensteinA. LamD.S.C. PasqualeL.R. WongT.Y. LamL.A. TingD.S.W. Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective.Prog. Retin. Eye Res.20218210090010.1016/j.preteyeres.2020.100900 32898686
     [Google Scholar]
  47. de la LastraJ.M.P. WardellS.J.T. PalT. de la Fuente-NunezC. PletzerD. From data to decisions: Leveraging artificial intelligence and machine learning in combating antimicrobial resistance – A comprehensive review.J. Med. Syst.20244817110.1007/s10916‑024‑02089‑5 39088151
     [Google Scholar]
  48. JavaidM. HaleemA. Pratap SinghR. SumanR. RabS. Significance of machine learning in healthcare: Features, pillars and applications.Int. J. Intell. Netw20223587310.1016/j.ijin.2022.05.002
     [Google Scholar]
  49. FanZ. YanZ. WenS. Deep learning and artificial intelligence in sustainability: A review of SDGs, renewable energy, and environmental health.Sustainability202315181349310.3390/su151813493
     [Google Scholar]
  50. TuckerA. WangZ. RotalintiY. MylesP. Generating high-fidelity synthetic patient data for assessing machine learning healthcare software.NPJ Digit. Med.20203114710.1038/s41746‑020‑00353‑9 33299100
     [Google Scholar]
  51. RellingM.V. KleinT.E. GammalR.S. Whirl-CarrilloM. HoffmanJ.M. CaudleK.E. The clinical pharmacogenetics implementation consortium: 10 years later.Clin. Pharmacol. Ther.2020107117117510.1002/cpt.1651 31562822
     [Google Scholar]
  52. ChenowethM.J. GiacominiK.M. PirmohamedM. HillS.L. van SchaikR.H.N. SchwabM. ShuldinerA.R. RellingM.V. TyndaleR.F. Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities.Clin. Pharmacol. Ther.20201071576110.1002/cpt.1664 31696505
     [Google Scholar]
  53. ZhaoChen KangJun LiYuwen WangYan TangXiaoying JiangZhenqi Carbon-based stimuli-responsive nanomaterials: Classification and application.Cyborg Bionic Syst.20234002210.34133/cbsystems.0022
     [Google Scholar]
  54. MaZ. ChenZ. ZhengX. WangT. YouY. ZouS. WangY. A biological immunity-based neuro prototype for few-shot anomaly detection with character embedding.Cyborg Bionic Syst.20245008610.34133/cbsystems.008638234315
     [Google Scholar]
  55. WangY. LiH. FanR. LvH. HuaS. XieH. TangT. LuoJ. XiaZ. The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage.Drug Des. Devel. Ther.2016102173218010.2147/DDDT.S107917 27462142
     [Google Scholar]
  56. SettyS.T. Scott-BoyerM.P. CuppensT. DroitA. New developments and possibilities in reanalysis and reinterpretation of whole exome sequencing datasets for unsolved rare diseases using machine learning approaches.Int. J. Mol. Sci.20222312679210.3390/ijms23126792 35743235
     [Google Scholar]
  57. ZhaoX. LiuT. HeY.N. FangW. LiX. JiangW. Comparison of the efficacy and safety of low-dose antihypertensive combinations in patients with hypertension: Protocol for a systematic review and network meta-analysis.BMJ Open20241410e08632310.1136/bmjopen‑2024‑086323 39448211
     [Google Scholar]
  58. FengC. WangY. XuJ. ZhengY. ZhouW. WangY. LuoC. Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect.Pharmaceutics20241612158210.3390/pharmaceutics16121582 39771561
     [Google Scholar]
  59. VisibelliA. RoncagliaB. SpigaO. SantucciA. The impact of artificial intelligence in the odyssey of rare diseases.Biomedicines202311388710.3390/biomedicines11030887 36979866
     [Google Scholar]
  60. SouzaÍ.P. AndrolageJ.S. BellatoR. A qualitative approach to rare genetic diseases: An integrative review of the national and international literature.Cien. Saude Colet.202224103683370010.1590/1413‑812320182410.17822019 31576998
     [Google Scholar]
  61. JeziorskiK. OlszewskiR. Artificial intelligence in oncology.Appl. Sci.202515126910.3390/app15010269
     [Google Scholar]
  62. DonadioD. TerryS.F. The application of artificial intelligence in the diagnosis of cancer and rare genetic diseases.Genet. Test. Mol. Biomarkers202327720320410.1089/gtmb.2023.29074.persp 37471205
     [Google Scholar]
  63. XuJ. YangP. XueS. SharmaB. Sanchez-MartinM. WangF. BeatyK.A. DehanE. ParikhB. Translating cancer genomics into precision medicine with artificial intelligence: Applications, challenges and future perspectives.Hum. Genet.2019138210912410.1007/s00439‑019‑01970‑5 30671672
     [Google Scholar]
  64. IvanisevicT. SewduthR.N. Multi-omics integration for the design of novel therapies and the identification of novel biomarkers.Proteomes20231143410.3390/proteomes11040034 37873876
     [Google Scholar]
  65. TaborH.K. GoldenbergA. What precision medicine can learn from rare genetic disease research and translation.AMA J. Ethics2018209E834E84010.1001/amajethics.2018.834 30242814
     [Google Scholar]
  66. FoksinskaA. CrowderC.M. CrouseA.B. HenriksonJ. ByrdW.E. RosenblattG. PattonM.J. HeK. Tran-NguyenT.K. ZhengM. RamseyS.A. AminN. OsborneJ. MightM. The precision medicine process for treating rare disease using the artificial intelligence tool mediKanren.Front. Artif. Intell.2022591021610.3389/frai.2022.910216 36248623
     [Google Scholar]
  67. SebastianA.M. PeterD. Artificial intelligence in cancer research: Trends, challenges and future directions.Life20221212199110.3390/life12121991 36556356
     [Google Scholar]
  68. TopolE.J. High-performance medicine: The convergence of human and artificial intelligence.Nat. Med.2019251445610.1038/s41591‑018‑0300‑7 30617339
     [Google Scholar]
  69. EstevaA. KuprelB. NovoaR.A. KoJ. SwetterS.M. BlauH.M. ThrunS. Dermatologist-level classification of skin cancer with deep neural networks.Nature2017542763911511810.1038/nature21056 28117445
     [Google Scholar]
  70. GulshanV. PengL. CoramM. StumpeM.C. WuD. NarayanaswamyA. VenugopalanS. WidnerK. MadamsT. CuadrosJ. KimR. RamanR. NelsonP.C. MegaJ.L. WebsterD.R. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs.JAMA2016316222402241010.1001/jama.2016.17216 27898976
     [Google Scholar]
  71. LitjensG. KooiT. BejnordiB.E. SetioA.A.A. CiompiF. GhafoorianM. van der LaakJ.A.W.M. van GinnekenB. SánchezC.I. A survey on deep learning in medical image analysis.Med. Image Anal.201742608810.1016/j.media.2017.07.005 28778026
     [Google Scholar]
  72. LeCunY. BengioY. HintonG. Deep learning.Nature2015521755343644410.1038/nature14539 26017442
     [Google Scholar]
  73. ObermeyerZ. EmanuelE.J. Predicting the future—big data, machine learning, and clinical medicine.N. Engl. J. Med.2016375131216121910.1056/NEJMp1606181 27682033
     [Google Scholar]
  74. WrightC.F. FitzPatrickD.R. FirthH.V. Paediatric genomics: Diagnosing rare disease in children.Nat. Rev. Genet.201819525326810.1038/nrg.2017.116 29398702
     [Google Scholar]
  75. YangY. MuznyD.M. ReidJ.G. BainbridgeM.N. WillisA. WardP.A. BraxtonA. BeutenJ. XiaF. NiuZ. HardisonM. PersonR. BekheirniaM.R. LeducM.S. KirbyA. PhamP. ScullJ. WangM. DingY. PlonS.E. LupskiJ.R. BeaudetA.L. GibbsR.A. EngC.M. Clinical whole-exome sequencing for the diagnosis of mendelian disorders.N. Engl. J. Med.2013369161502151110.1056/NEJMoa1306555 24088041
     [Google Scholar]
  76. LionelA.C. CostainG. MonfaredN. WalkerS. ReuterM.S. HosseiniS.M. ThiruvahindrapuramB. MericoD. JoblingR. NalpathamkalamT. PellecchiaG. SungW.W.L. WangZ. BikangagaP. BoelmanC. CarterM.T. CordeiroD. CytrynbaumC. DellS.D. DhirP. DowlingJ.J. HeonE. HewsonS. HirakiL. Inbar-FeigenbergM. KlattR. KronickJ. LaxerR.M. LichtC. MacDonaldH. Mercimek-AndrewsS. Mendoza-LondonoR. PiscioneT. SchneiderR. SchulzeA. SilvermanE. SiriwardenaK. SneadO.C. SondheimerN. SutherlandJ. VincentA. WassermanJ.D. WeksbergR. ShumanC. CarewC. SzegoM.J. HayeemsR.Z. BasranR. StavropoulosD.J. RayP.N. BowdinS. MeynM.S. CohnR.D. SchererS.W. MarshallC.R. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test.Genet. Med.201820443544310.1038/gim.2017.119 28771251
     [Google Scholar]
  77. WengerA.M. GuturuH. BernsteinJ.A. BejeranoG. Systematic reanalysis of clinical exome data yields additional diagnoses: Implications for providers.Genet. Med.201719220921410.1038/gim.2016.88 27441994
     [Google Scholar]
  78. TrujillanoD. Bertoli-AvellaA.M. Kumar KandaswamyK. WeissM.E.R. KösterJ. MaraisA. PakniaO. SchröderR. Garcia-AznarJ.M. WerberM. BrandauO. Calvo del CastilloM. BaldiC. WesselK. KishoreS. NahavandiN. EyaidW. Al RifaiM.T. Al-RumayyanA. Al-TwaijriW. AlothaimA. AlhashemA. Al-SannaaN. Al-BalwiM. AlfadhelM. RolfsA. Abou JamraR. Clinical exome sequencing: Results from 2819 samples reflecting 1000 families.Eur. J. Hum. Genet.201725217618210.1038/ejhg.2016.146 27848944
     [Google Scholar]
  79. RettererK. JuusolaJ. ChoM.T. VitazkaP. MillanF. GibelliniF. Vertino-BellA. SmaouiN. NeidichJ. MonaghanK.G. McKnightD. BaiR. SuchyS. FriedmanB. TahilianiJ. Pineda-AlvarezD. RichardG. BrandtT. HaverfieldE. ChungW.K. BaleS. Clinical application of whole-exome sequencing across clinical indications.Genet. Med.201618769670410.1038/gim.2015.148 26633542
     [Google Scholar]
  80. StarkZ. TanT.Y. ChongB. BrettG.R. YapP. WalshM. YeungA. PetersH. MordauntD. CowieS. AmorD.J. SavarirayanR. McGillivrayG. DownieL. EkertP.G. ThedaC. JamesP.A. Yaplito-LeeJ. RyanM.M. LeventerR.J. CreedE. MaccioccaI. BellK.M. OshlackA. SadedinS. GeorgesonP. AndersonC. ThorneN. GaffC. WhiteS.M. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders.Genet. Med.201618111090109610.1038/gim.2016.1 26938784
     [Google Scholar]
  81. SmedleyD. SmithK.R. MartinA. ThomasE.A. McDonaghE.M. CiprianiV. EllingfordJ.M. ArnoG. TucciA. VandrovcovaJ. ChanG. WilliamsH.J. RatnaikeT. WeiW. StirrupsK. IbanezK. MoutsianasL. WielscherM. NeedA. BarnesM.R. VestitoL. BuchananJ. WordsworthS. AshfordS. RehmströmK. LiE. FullerG. TwissP. Spasic-BoskovicO. HalsallS. FlotoR.A. PooleK. WagnerA. MehtaS.G. GurnellM. BurrowsN. JamesR. PenkettC. DewhurstE. GräfS. MapetaR. KasanickiM. HaworthA. SavageH. BabcockM. ReeseM.G. BaleM. BapleE. BoustredC. BrittainH. de BurcaA. BledaM. DevereauA. HalaiD. HaraldsdottirE. HyderZ. KasperaviciuteD. PatchC. PolychronopoulosD. MatchanA. SultanaR. RytenM. TavaresA.L.T. TregidgoC. TurnbullC. WellandM. WoodS. SnowC. WilliamsE. LeighS. FoulgerR.E. DaughertyL.C. NiblockO. LeongI.U.S. WrightC.F. DaviesJ. CrichtonC. WelchJ. WoodsK. AbulhoulL. AuroraP. BockenhauerD. BroomfieldA. ClearyM.A. LamT. DattaniM. FootittE. GanesanV. GrunewaldS. Compeyrot-LacassagneS. MuntoniF. PilkingtonC. QuinlivanR. ThaparN. WallisC. WedderburnL.R. WorthA. BueserT. ComptonC. DeshpandeC. FassihiH. HaqueE. IzattL. JosifovaD. MohammedS. RobertL. RoseS. RuddyD. SarkanyR. SayG. ShawA.C. WolejkoA. HabibB. BurnsG. HunterS. GrocockR.J. HumphrayS.J. RobinsonP.N. HaendelM. SimpsonM.A. BankaS. Clayton-SmithJ. DouzgouS. HallG. ThomasH.B. O’KeefeR.T. MichaelidesM. MooreA.T. MalkaS. PontikosN. BrowningA.C. StraubV. GormanG.S. HorvathR. QuintonR. SchaeferA.M. Yu-Wai-ManP. TurnbullD.M. McFarlandR. TaylorR.W. O’ConnorE. YipJ. NewlandK. MorrisH.R. PolkeJ. WoodN.W. CampbellC. CampsC. GibsonK. KoellingN. LesterT. NémethA.H. PallesC. PatelS. RoyN.B.A. SenA. TaylorJ. CacheiroP. JacobsenJ.O. SeabyE.G. DavisonV. ChittyL. DouglasA. NareshK. McMullanD. EllardS. TempleI.K. MumfordA.D. WilsonG. BealesP. Bitner-GlindziczM. BlackG. BradleyJ.R. BrennanP. BurnJ. ChinneryP.F. ElliottP. FlinterF. HouldenH. IrvingM. NewmanW. RahmanS. SayerJ.A. TaylorJ.C. WebsterA.R. WilkieA.O.M. OuwehandW.H. RaymondF.L. ChisholmJ. HillS. BentleyD. ScottR.H. FowlerT. RendonA. CaulfieldM. 100,000 genomes pilot on rare-disease diagnosis in health care — Preliminary report.N. Engl. J. Med.2021385201868188010.1056/NEJMoa2035790 34758253
     [Google Scholar]
  82. JacobH.J. AbramsK. BickD.P. BrodieK. DimmockD.P. FarrellM. Genomics in clinical practice: Lessons from the front lines.Sci. Transl. Med.201810463eaao017710.1126/scitranslmed.3006468 23863829
     [Google Scholar]
  83. Gonzalez-GarayM.L. McGuireA.L. PereiraS. CaskeyC.T. Personalized genomic disease risk of volunteers.Proc. Natl. Acad. Sci. USA201311042169571696210.1073/pnas.1315934110 24082139
     [Google Scholar]
  84. WrightC.F. McRaeJ.F. ClaytonS. GalloneG. AitkenS. FitzGeraldT.W. JonesP. PrigmoreE. RajanD. LordJ. SifrimA. KelsellR. ParkerM.J. BarrettJ.C. HurlesM.E. FitzPatrickD.R. FirthH.V. Making new genetic diagnoses with old data: Iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders.Genet. Med.201820101216122310.1038/gim.2017.246 29323667
     [Google Scholar]
  85. JameiM. MarciniakS. EdwardsD. WraggK. FengK. BarnettA. Rostami-HodjeganA. The Simcyp population based simulator: Architecture, implementation, and quality assurance.In Silico Pharmacol.201319Jun 3;10.1186/2193‑9616‑1‑9 25505654
     [Google Scholar]
  86. TyzackJ.D. KirchmairJ. Computational methods and tools to predict cytochrome P450 metabolism for drug discovery.Chem. Biol. Drug Des.201993437738610.1111/cbdd.13445 30471192
     [Google Scholar]
  87. SjögrenE. ThörnH. TannergrenC. In silico modeling of gastrointestinal drug absorption: Predictive performance of three physiologically based absorption models.Mol. Pharm.20161361763177810.1021/acs.molpharmaceut.5b00861 26926043
     [Google Scholar]
  88. LelieveldS.H. ReijndersM.R.F. PfundtR. YntemaH.G. KamsteegE.J. de VriesP. de VriesB.B.A. WillemsenM.H. KleefstraT. LöhnerK. VreeburgM. StevensS.J.C. van der BurgtI. BongersE.M.H.F. StegmannA.P.A. RumpP. RinneT. NelenM.R. VeltmanJ.A. VissersL.E.L.M. BrunnerH.G. GilissenC. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability.Nat. Neurosci.20161991194119610.1038/nn.4352 27479843
     [Google Scholar]
  89. RajpurkarP. IrvinJ. BallR.L. ZhuK. YangB. MehtaH. DuanT. DingD. BagulA. LanglotzC.P. PatelB.N. YeomK.W. ShpanskayaK. BlankenbergF.G. SeekinsJ. AmrheinT.J. MongD.A. HalabiS.S. ZuckerE.J. NgA.Y. LungrenM.P. Deep learning for chest radiograph diagnosis: A retrospective comparison of the CheXNeXt algorithm to practicing radiologists.PLoS Med.20181511e100268610.1371/journal.pmed.1002686 30457988
     [Google Scholar]
  90. BeamA.L. KohaneI.S. Big data and machine learning in health care.JAMA2018319131317131810.1001/jama.2017.18391 29532063
     [Google Scholar]
  91. KellyC.J. KarthikesalingamA. SuleymanM. CorradoG. KingD. Key challenges for delivering clinical impact with artificial intelligence.BMC Med.201917119510.1186/s12916‑019‑1426‑2 31665002
     [Google Scholar]
  92. AmannJ. BlasimmeA. VayenaE. FreyD. MadaiV.I. Explainability for artificial intelligence in healthcare: A multidisciplinary perspective.BMC Med. Inform. Decis. Mak.202020131010.1186/s12911‑020‑01332‑6 33256715
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002383220250729100138
Loading
Emerging Approaches in Data-Driven Drug Discovery for Rare Diseases
Current Drug Metabolism 26, 561 (2025); https://doi.org/10.2174/0113892002383220250729100138
/content/journals/cdm/10.2174/0113892002383220250729100138
/content/journals/cdm/10.2174/0113892002383220250729100138
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): artificial intelligence; computational drug discovery; digital twin models; high-throughput screening; machine learning; personalized medicine; Rare diseases

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test